Tahoun, A., Elgazzar, M., Shedid, A., Rezk, A. (2021). Fixed Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: RCT. test, 6(5), 109-115. doi: 10.21608/bjas.2021.199035
A.E. Tahoun; M.A. Elgazzar; A.A. Shedid; A.Y. Rezk. "Fixed Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: RCT". test, 6, 5, 2021, 109-115. doi: 10.21608/bjas.2021.199035
Tahoun, A., Elgazzar, M., Shedid, A., Rezk, A. (2021). 'Fixed Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: RCT', test, 6(5), pp. 109-115. doi: 10.21608/bjas.2021.199035
Tahoun, A., Elgazzar, M., Shedid, A., Rezk, A. Fixed Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: RCT. test, 2021; 6(5): 109-115. doi: 10.21608/bjas.2021.199035

Fixed Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: RCT

Benha Journal of Applied Sciences
Article 18, Volume 6, Issue 5, September 2021, Pages 109-115    PDF (289.22 K)
Document Type: Original Research Papers
DOI: 10.21608/bjas.2021.199035
Authors
A.E. Tahoun1; M.A. Elgazzar2; A.A. Shedid2; A.Y. Rezk2
1obstetrics and gynecology, Alsaadieen hospital, Ministry of health, Egypt
2obstetrics and gynecology, Dept.,Faculty of Medicine, Benha Univ., Benha, Egypt
Abstract
Background: In vitro fertilization for women with polycystic ovarian syndrome is an essential (PCOS). New methods to improve clinical outcomes are still needed. Objective: this research investigated the effectiveness of PPOS and compared it with the standard PCOS antagonist regimen. Materials and procedures: A total of 76 PCOS women eligible for aided therapy of reproductive technology were recruited in this RCT from February 2020 to May 2021 and put in random two groups (n=38/per group). Since the sixth day of the cycle, the PPOS group has received 20 mg/day orally of Dydrogesterone, while the control group received antagonist treatment. In addition to safety, our results were chemical and clinical pregnancy. Results: oocyte retrieval counts, oocyte metaphase II (MII) and MI have been comparable. There are also comparable numbers of fertilized oocytes and cleaved embryos without any statistical difference in the number of injected oocytes. Lower antagonistic gonadotropin dosage than the PPOS group (2957.8±301.9 vs 3197.4±545.9), with higher stimulation times respectively in the PPOS group than the antagonist. Similar findings across both main outcome groups (OHSS) with no instances of  FPPOS and just one case (2.6 percent) of moderate OHSS antagonists. Similar findings also for secondary results (biochemical pregnancy rate , clinical pregnancy rate and miscarriage rate). Conclusion: the established In PCOS patients receiving IVF/ICSI therapy, PPOS is a safe and successful procedure.
Keywords
Progesterone; Polycystic ovarian syndrome; controlled ovarian stimulation; Frozen-thawed embryo transfer; Pregnancy rate
Statistics
Article View: 194
PDF Download: 1,023